HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.

[1]  P. Kantoff,et al.  Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Stockler,et al.  Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. , 2016, The Lancet. Oncology.

[3]  S. Upadhyay,et al.  Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy , 2016, Nature.

[4]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[5]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[6]  K. Nastiuk,et al.  Variant allele of HSD3B1 increases progression to castration‐resistant prostate cancer , 2015, The Prostate.

[7]  Dustin R. Bunch,et al.  Conversion of abiraterone to D4A drives antitumor activity in prostate cancer , 2015, Nature.

[8]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[9]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[10]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[11]  P. Nelson,et al.  A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer , 2013, Cell.

[12]  Donna L Berry,et al.  Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.

[13]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[14]  C. Guillemette,et al.  Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression , 2012, Clinical Cancer Research.

[15]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[16]  M. Nissen,et al.  Comparison of a multiplexed MassARRAY system with real-time allele-specific PCR technology for genotyping of methicillin-resistant Staphylococcus aureus. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  P. Kantoff,et al.  SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[19]  J. Stanford,et al.  Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer Outcomes , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[20]  H. Guchelaar,et al.  Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. , 2010, The Journal of molecular diagnostics : JMD.

[21]  유희철.  간담췌 종양에 대한 American Joint Committee on Cancer (AJCC) 종양 병기 7판 소개 , 2010 .

[22]  N. Sewankambo,et al.  Comparison of methods in the recovery of nucleic acids from archival formalin-fixed paraffin-embedded autopsy tissues. , 2010, Analytical biochemistry.

[23]  L. Schwartz,et al.  Assessing outcomes in prostate cancer clinical trials , 2008, Cancer.

[24]  D. Trump.  Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer , 2008 .

[25]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[26]  A. Renshaw,et al.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. , 2008, JAMA.

[27]  Katherine S Panageas,et al.  When you look matters: the effect of assessment schedule on progression-free survival. , 2007, Journal of the National Cancer Institute.

[28]  Michael W Kattan,et al.  Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[30]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Timothy F. Donahue,et al.  Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. , 2004, The Journal of urology.

[32]  Paul Oeth,et al.  MALDI-TOF mass spectrometry , 2004, Molecular biotechnology.

[33]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[34]  U. Lehmann,et al.  Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. , 2001, Methods.

[35]  P. Walsh.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 2000, The Journal of urology.

[36]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[37]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[38]  B. Chauvet,et al.  [Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin]. , 1998, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[39]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[40]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[41]  J. Moul,et al.  Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. , 2008, The Journal of urology.

[42]  Jacques Simard,et al.  Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. , 2005, Endocrine reviews.